Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SAN DIEGO, Oct. 17, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced that the company has received a new patent grant, Process For The Purification Of Heparan Sulfate And Use Thereof In Cosmetological And Dermatological Preparations (U.S. Patent No. 9,4330,099) by the United States Patent and Trademark Office (USPTO). The company’s patent estate has now produced patents in Europe and the United States, further strengthening its ability to distribute innovative skin care products worldwide.
“The issuance of this patent is a major milestone for the company and comes at a time when we are gaining significant traction,” said Laurent Combredet, Chief Executive Officer. “This further solidifies our IP position and adds to our vision of becoming a leading aesthetics company dedicated to pioneering glycosaminoglycan science.”
“Our focus is to remain dedicated to the development of products based on rigorous science and clinical research,” said Faheem Hasnain, Chairman of the Board of Directors. “This patent grant allows us to continue developing innovative and market disrupting technologies in the US and abroad.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.
Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
